22,197 results match your criteria Anticancer research[Journal]


Errata.

Authors:

Anticancer Res 2020 Jul;40(7):4205

View Article

Download full-text PDF

Source

Errata.

Authors:

Anticancer Res 2020 Jul;40(7):4205

View Article

Download full-text PDF

Source

Recurrent Leiomyosarcoma of the Small Bowel: A Case Series.

Anticancer Res 2020 Jul;40(7):4199-4204

Department of General Surgery, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, University of Genoa, Genoa, Italy.

Background/aim: Leiomyosarcoma is an extremely rare, small bowel neoplasm (2% of all gastrointestinal tumours). Early diagnosis is challenging due to the slow growth of the cancer. The biological behaviour of this group of tumours is aggressive, and the first-line treatment is surgical resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14420DOI Listing

Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma.

Anticancer Res 2020 Jul;40(7):4191-4198

Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

Background/aim: Tumoral calcification after chemotherapy or radiation therapy has been reported in various cancer patients, but not after radioembolization. The purpose of this study was to evaluate the prognostic value of radioembolization-induced tumor calcification of hepatocellular carcinoma (HCC) treated by radioembolization.

Patients And Methods: This retrospective study comprised patients with single nodular HCC who underwent yttrium-90 radioembolization between November 2015 and April 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14419DOI Listing

A Single Institution's Experience of Definitive Radiotherapy Using Volumetric-modulated Arc Therapy for Hypopharyngeal Cancers.

Anticancer Res 2020 Jul;40(7):4183-4190

Department of Radiation Oncology, Hiroshima University Hospital, Hiroshima, Japan.

Background/aim: The present study aimed to analyze the treatment outcome after definitive radiotherapy (dRT) using volumetric-modulated arc therapy (VMAT) in patients with hypopharyngeal cancer (HPC), including an examination of late toxicities.

Patients And Methods: A total of 62 patients with HPC, who underwent dRT using VMAT, were analyzed. Overall survival (OS), progression-free survival (PFS), laryngoesophageal dysfunction-free survival (LEDFS), and locoregional control (LRC) were calculated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14418DOI Listing

Sorafenib Might Induce Sarcopenia in Patients With Hepatocellular Carcinoma by Inhibiting Carnitine Absorption.

Anticancer Res 2020 Jul;40(7):4173-4182

Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.

Background/aim: Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of cancers. Sorafenib, an oral multi-target TKI, improves the median overall survival time in patients with hepatocellular carcinoma (HCC). It also inhibits the absorption of carnitine by down-regulating the human organic cationic transporter OCTN2 located largely in the small intestinal mucosa and skeletal muscle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14417DOI Listing

Prognostic Impact of Geriatric Nutritional Risk Index in Patients With Synchronous Colorectal Liver Metastasis.

Anticancer Res 2020 Jul;40(7):4165-4171

Department of Gastroenterological Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Background/aim: The Geriatric Nutritional Risk Index (GNRI) is a prognostic indicator for several cancers; however, the association between the GNRI and colorectal liver metastasis (CRLM) remains unknown.

Patients And Methods: Eighty patients who underwent hepatectomy for synchronous CRLM were divided into two groups based on the GNRI.

Results: The preoperative CA19-9 levels were significantly higher in the low (GNRI ≤98; n=30) than the normal GNRI group (GNRI >98; n=50). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14416DOI Listing

Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.

Anticancer Res 2020 Jul;40(7):4157-4163

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Background/aim: The efficacy of trifluridine/thymidine phosphorylase inhibitor (FTD/TPI) plus bevacizumab as later-line treatment for metastatic colorectal cancer (mCRC) has been demonstrated. However, little is known about the impact of a usage history of bevacizumab in front-line treatment on the clinical benefit of combining bevacizumab with FTD/TPI.

Patients And Methods: A total of 62 patients with mCRC treated with FTD/TPI±bevacizumab was enrolled and assessed for chemotherapeutic efficacy and adverse events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14415DOI Listing

C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin.

Anticancer Res 2020 Jul;40(7):4147-4156

Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Japan

Background/aim: We investigated the efficacy of neutrophil-to-lymphocyte ratio (NLR), absolute lymphocyte count (ALC), and C-reactive protein (CRP) in predicting overall survival of metastatic breast cancer patients treated with eribulin.

Patients And Methods: Overall, 74 patients treated with eribulin were enrolled and their baseline levels of NLR, ALC, and CRP retrieved. Cutoff values of NLR, ALC, and CRP were set at 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14414DOI Listing

Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm.

Anticancer Res 2020 Jul;40(7):4137-4145

First Department of Medicine (Cardiology), University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, European Centre for AngioScience (ECAS), Mannheim, Germany.

Background/aim: Lung diseases are common in patients with abdominal aortic aneurysms (AAA). This study evaluates the prevalence of lung cancer (LC) in high-risk patients screened for AAA.

Patients And Methods: Six hundred and one male patients (≥65 years of age, cardiovascular high-risk profile) were enrolled and followed prospectively over a median of 16. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14413DOI Listing

Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report.

Anticancer Res 2020 Jul;40(7):4131-4135

Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Oita, Japan.

Background: Immune responses due to radiotherapy and immune checkpoint inhibitors potentially have synergistic effects.

Case Report: Here, we report a 65-year-old Japanese woman presenting with high-grade endometrial cancer. She was diagnosed with carcinosarcoma, stage IB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14412DOI Listing

Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.

Anticancer Res 2020 Jul;40(7):4123-4129

Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.

Background/aim: The efficacy of pembrolizumab for intrahepatic cholangiocellular carcinoma (IHCCC) is not widely reported.

Case Report: We began pembrolizumab treatment in a 69-year-old male with recurrent IHCCC at 18 months after his surgery because of the proven microsatellite instability (MSI)-high status. The patient had partial response, with an 82. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14411DOI Listing

Magnetic Resonance and Ultrasound Fusion Imaging to Characterise Ovarian Masses: A Feasibility Study.

Anticancer Res 2020 Jul;40(7):4115-4121

Department of Obstetrics and Gynaecology and Reproductive Médecine, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Background/aim: Magnetic resonance (MR) and ultrasound (US) fusion imaging (MR-US fusion) is already used to guide prostate biopsies and has been proven accurate for diagnosing cervical cancer. In this study, we aimed to evaluate the feasibility and performance of MR-US fusion for characterizing adnexal masses.

Patients And Methods: A retrospective study was conducted between 2014 and 2018 including women referred to our Gynaecological Oncology Department for characterization of an adnexal mass (n=106). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14410DOI Listing

Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma.

Anticancer Res 2020 Jul;40(7):4105-4113

Department of Pathology, Kurume University School of Medicine, Kurume, Japan.

Background/aim: Assessment of the biological behavior of tumors is important for choosing an appropriate cancer therapy. In hepatocellular carcinoma (HCC), the biological behaviour can be assessed by tumor morphology and molecular biology. This study investigated the usefulness of tumor tissue biopsy for predicting the biological behavior of HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14409DOI Listing

The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.

Anticancer Res 2020 Jul;40(7):4095-4104

Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.

Background/aim: To evaluate treatment schedules involving concurrent chemoradiotherapy in stage III non-small cell lung cancer (NSCLC) using the tumor control probability (TCP) and normal tissue complication probability (NTCP) parameters.

Patients And Methods: The standard schedules were compared with two types of schedules, the dose escalation and the short-term schedules. Standard schedules were 60-74 Gy in 30-37 fractions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14408DOI Listing

The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma.

Anticancer Res 2020 Jul;40(7):4087-4093

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

Background/aim: Hypertension is a risk factor for occurrence of renal cell carcinoma; however, it remains unclear whether hypertension affects development and prognosis of renal cell carcinoma. This study evaluated the impact of hypertension on the progression of renal cell carcinoma.

Patients And Methods: Renal cell carcinoma patients who were treated from October 2007 to December 2018 at our Institution were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14407DOI Listing

Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients.

Anticancer Res 2020 Jul;40(7):4081-4086

Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.

Background/aim: Treatment for elderly patients with few brain metastases is controversial. A score was generated to predict distant brain metastases (DBMs) after stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT).

Patients And Methods: Ten characteristics were retrospectively analyzed for freedom from new DBMs in 104 elderly patients receiving SRS or FSRT alone for 1-3 brain metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14406DOI Listing

Retzius-sparing Robotic-assisted Radical Prostatectomy Facilitates Early Continence Regardless of Neurovascular Bundle Sparing.

Anticancer Res 2020 Jul;40(7):4075-4080

Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.

Background/aim: Retzius-sparing robotic-assisted radical prostatectomy (RARP) has had better results in early continence rate and comparable oncological safety compared to the retropubic approach. However, the role the neurovascular bundle (NVB) sparing plays in the rate of early continence after catheter removal remains unclear. In this study, we sought to compare the early continence rate between Retzius-sparing RARP and the retropubic approach RARP to assess whether NVB sparing affects the continence rate in patients with prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14405DOI Listing

The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer.

Anticancer Res 2020 Jul;40(7):4067-4074

Department of Surgery, Yokohama City University, Yokohama, Japan.

Background: The aim of this study was to evaluate the impact of postoperative infectious complications on long-term outcomes after curative resection of gastric cancer.

Patients And Methods: Patients who underwent curative gastrectomy with lymphadenectomy for gastric cancer at Yokohama City University and Kanagawa Cancer Center from January 2000 to August 2015 were retrospectively selected from medical records. Clinicopathological factors between patients with and without infectious complications were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14404DOI Listing

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.

Anticancer Res 2020 Jul;40(7):4059-4066

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.

Background/aim: To study the long-term clinical efficacy and tolerability of ibrutinib monotherapy in real-world relapsed and refractory chronic lymphocytic leukemia (RR-CLL) patients outside clinical trials.

Patients And Methods: Clinical data of 171 RR-CLL patients treated with ibrutinib were collected within the observational study of the Polish Adult Leukemia Study Group.

Results: Median patient age was 64 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14403DOI Listing

Proposal of a Classification System for Adenocarcinoma Involving the Ileocecal Valve (Bauhin's Valve): A Retrospective Study of 689 Right Hemicolectomized Patients.

Anticancer Res 2020 Jul;40(7):4053-4057

Department of Medical and Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology "Sapienza", St. Andrea Hospital, Rome, Italy.

Background/aim: As of 2020, adenocarcinoma arising in the ileocecal valve (ICV-A) has been examined along with cecal and right colon cancer (RCC) under the collective heading "ileocecal" tumor. We propose a new classification system for this cancer.

Patients And Methods: We retrospectively analyzed RCC patients from 2003 to 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14402DOI Listing

Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab.

Anticancer Res 2020 Jul;40(7):4047-4051

Department of Pharmacy, Osaka City University Hospital, Osaka, Japan.

Background/aim: Infusion reactions (IRs) often occur with trastuzumab. Although premedication by non-steroidal anti-inflammatory drugs can be effective to a certain extent, IRs are still common and infrequently severe. Therefore, a predictive marker that can select patients requiring further prophylaxis is useful for appropriate prevention, but remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14401DOI Listing

Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma.

Anticancer Res 2020 Jul;40(7):4041-4046

Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.

Aim: Modern radiotherapy (RT) technique and therapy de-escalation have led to encouraging results in lymphoma management. In this study, we aimed to describe the oncological and toxicity outcome in patients with ocular adnexal lymphoma.

Patients And Methods: A total of 45 patients with 52 orbital lesions who were treated at our Institution between 2003 and 2019 were considered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14400DOI Listing

Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer.

Anticancer Res 2020 Jul;40(7):4033-4040

Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.

Background/aim: This study investigated the feasibility of an integrated scoring system of preoperative prognostic parameters using data from before/after neoadjuvant therapy in patients with borderline resectable pancreatic cancer (BRPC).

Patients And Methods: We constructed and analyzed a prognostic scoring system using factors that were previously reported to be significant prognostic indicators or predictors of histological response.

Results: We analyzed 28 consecutive patients with BRPC who underwent neoadjuvant therapy and subsequent surgical resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14399DOI Listing

Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.

Anticancer Res 2020 Jul;40(7):4029-4032

Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.

The synchronous diagnosis of two or more primary malignancies in a patient is overall rare. This is a case report of a 70-year-old female with a history of skin squamous cell carcinoma presenting with occult hematochezia. Colonoscopy and biopsy results confirmed a microsatellite stable (MMS) adenocarcinoma in the ascending colon, and subsequent computed tomography (CT) scans identified a 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14398DOI Listing

Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer.

Anticancer Res 2020 Jul;40(7):4023-4027

Department of Cardiovascular Surgery, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

Background/aim: Different tumor markers and systemic inflammation have been linked with cancer development and poor outcome. We aimed to establish a novel non-invasive prognostic index for patients with resectable non-small cell lung cancer (NSCLC) based on serum carcinoembryonic antigen (CEA) and C-reactive protein (CRP).

Patients And Methods: Four hundred and sixty-two patients curatively resected for NSCLC between 2008 and 2014 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14397DOI Listing

Skin Architecture, Kidney Transplantation, and Their Relationship to Basal and Squamous Cell Carcinomas.

Anticancer Res 2020 Jul;40(7):4017-4022

Department of Translational Medical Sciences, University of Campania "L. Vanvitelli", Naples, Italy

Background/aim: Squamous cell carcinoma (SCC) is highly prevalent in kidney transplant patients (KT). It is characterized by the presence of an inflammatory infiltrate. In this study, we examined the presence of similar infiltrates in intact skin, which could be regarded as a precancerous step. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14396DOI Listing

Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.

Anticancer Res 2020 Jul;40(7):4011-4015

Department of Medical Oncology, Center GF Leclerc, Dijon, France

Background/aim: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX.

Patients And Methods: Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14395DOI Listing

Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.

Anticancer Res 2020 Jul;40(7):4001-4010

Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.

Background/aim: This study was conducted to comprehensively evaluate programmed cell death ligand 1 (PD-L1) expression, and analyze the clinical and prognostic implications of PD-L1 expression in oropharyngeal squamous cell carcinoma (OPSCC).

Patients And Methods: We evaluated the expression of PD-L1 using the antibodies SP263 and SP142 in 106 patients with OPSCC, using immunohistochemistry. PD-L1 expression was subdivided into tumor cell score (TC), immune cell score (IC), and combined score (CS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14394DOI Listing

Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.

Anticancer Res 2020 Jul;40(7):3995-4000

Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, U.S.A.

We present here the case of a 39-year-old man with metastatic pancreatic carcinoma receiving chemotherapy with the combination of gemcitabine and nab-paclitaxel as part of a clinical trial. Despite an impressive response to therapy, he ultimately developed profound anasarca, renal insufficiency, progressive cytopenias, and malignant hypertension 6 months into his treatment course. The diagnosis of gemcitabine-associated thrombotic microangiopathy (G-TMA) was made based on renal biopsy, and receipt of the anti-C5 monoclonal antibody eculizumab proved successful at reversing his deteriorating clinical course and improving his laboratory parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14393DOI Listing

Russell Body Gastroesophagitis Concurrent With Barrett's Esophagus.

Anticancer Res 2020 Jul;40(7):3991-3994

Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, U.S.A.

Background: Russell body gastroesophagitis is a rare entity characterized by the accumulation of immunoglobulins within the cytoplasm of plasma cells.

Case Report: Here, we present the case of a 41-year-old male with history of gastroesophageal reflux disease who presented with nausea, vomiting, and altered mental status. Candida esophagitis was noted on upper endoscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14392DOI Listing

Features of Hepatocellular Carcinoma With Micro Hepatic Vein Invasion and their Correlation With Hepatitis B and C Virus.

Anticancer Res 2020 Jul;40(7):3983-3990

Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan.

Background/aim: Few studies have studied micro hepatic vein invasion in hepatocellular carcinoma (HCC). We explored the correlation between hepatic vein invasion and hepatitis B/C virus infection.

Patients And Methods: Between April 2000 and February 2018, 869 patients underwent liver resection for HCC at a single center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14391DOI Listing

Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer.

Anticancer Res 2020 Jul;40(7):3973-3981

Gynecology and Obstetrics Department, University of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Background/aim: HER2-positive breast cancers eventually relapse in about one third of patients. Is anti-HER2-directed therapy with Herceptin® (trastuzumab) effective in re-treatment? Between 2008 and 2018, 216 patients with recurrent HER2-positive breast cancer (BC) were re-treated with Herceptin (HER) during first-line therapy. This study assessed the effectiveness and tolerability of re-treatment with HER. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14390DOI Listing

Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology.

Anticancer Res 2020 Jul;40(7):3967-3972

Department of Urology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.

Background/aim: There is a need to diagnose early bladder cancer by non-invasive tests. This study aimed to explore the clinical value of three non-invasive methods, UBC Rapid, ultrasound (US), and urine cytology, separately and in combination, for the primary diagnosis and surveillance of bladder-cancer.

Patients And Methods: Urine samples were obtained from 106 patients who presented with symptoms of bladder cancer and patients followed-up after transurethral resection of bladder tumors (TURB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14389DOI Listing

Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis.

Anticancer Res 2020 Jul;40(7):3961-3965

Department of Radiation Oncology, University of Lübeck, Lübeck, Germany

Background/aim: Seizures represent a common manifestation of gliomas. This study evaluated the prevalence of pre-radiotherapy seizures, potential risk factors and associations with survival.

Patients And Methods: Eight factors were analyzed in 222 patients for associations with seizures including number, size and location of glioma, World Health Organization (WHO) grade, performance score, gender, age and upfront resection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14388DOI Listing

Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma.

Anticancer Res 2020 Jul;40(7):3953-3960

Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Background/aim: To examine the factors influencing the introduction of the second-line chemotherapy and discuss the selection of first-line agent for hepatocellular carcinoma (HCC).

Patients And Methods: We retrospectively studied 154 patients with HCC who received sorafenib therapy.

Results: A total of 109 (70. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14387DOI Listing

Evaluating the Platelet Distribution Width-to-Plateletcrit Ratio as a Prognostic Marker for Patients With Breast Cancer.

Anticancer Res 2020 Jul;40(7):3947-3952

Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Oita, Japan.

Aim: This study aimed to evaluate plateletcrit (PCT) and platelet distribution width-to-PCT ratio (PDW/PCT) as potential prognostic biomarkers in patients with breast cancer.

Patients And Methods: Information of 337 patients was retrospectively reviewed. The Cox regression proportional hazards model was used to evaluate the prognostic value of PCT and PDW/PCT compared to the platelet distribution width-to-platelet count ratio (PDW/P) and red cell distribution width-to-platelet count ratio (RDW/P). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14386DOI Listing

GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.

Anticancer Res 2020 Jul;40(7):3939-3945

ORACLE-Centre d'Oncologie de Gentilly, Nancy, France.

Background: Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.

Patients And Methods: Patients with ROC after at least one platinum-based regimen received 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14385DOI Listing

The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer.

Anticancer Res 2020 Jul;40(7):3931-3937

Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.

Background/aim: Extracellular water-to-total body water ratio (ECW/TBW) measured by bioelectrical impedance analysis (BIA) reportedly predicts clinical outcomes of various diseases. The aim of this retrospective study was to examine the association between ECW/TBW and therapeutic durability of chemotherapy and/or immune checkpoint inhibitors in advanced lung cancer.

Patients And Methods: Patients with advanced lung cancer underwent BIA before chemotherapy and/or treatment with immune checkpoint inhibitors at our hospital between June 2018 and November 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14384DOI Listing

Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study.

Anticancer Res 2020 Jul;40(7):3925-3929

Derby Gynaecological Cancer Centre, University Hospitals of Derby and Burton, Derby, U.K.

Background/aim: CHORUS and EORTC55971 trials demonstrated that neoadjuvant chemotherapy followed by interval debulking surgery (IDS) or primary debulking surgery (PDS) offered the same survival rates. These trials have since been criticised due to poor surgical complexity. We compared overall (OS), progression free (PFS), and platinum sensitivity in advanced ovarian cancer (AOC) patients undergoing IDS or PDS, who had received either intermediate or high complexity surgery to achieve complete cytoreduction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14383DOI Listing

Reflector-guided Localization of Non-palpable Breast Lesions: The First Reported European Evaluation of the SAVI SCOUT® System.

Anticancer Res 2020 Jul;40(7):3915-3924

The London Breast Institute, the Princess Grace Hospital, London, U.K.

Background: Wire-guided localization (WGL) has been the mainstay for localizing non-palpable breast lesions before excision. Due to its limitations, various wireless alternatives have been developed. In this prospective study, we evaluate the role of radiation-free wireless localization using the SAVI SCOUT® localization at a European centre. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14382DOI Listing

Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.

Anticancer Res 2020 Jul;40(7):3905-3913

Biostatistics Department, Centre Léon Bérard, Lyon, France.

Background/aim: Vinorelbine is indicated for use in the treatment of MBC as a single agent or in combination but there is little real world data on this molecule and even less on its oral form. We exploited the Unicancer Epidemiology Strategy Medical-Economics (ESME) metastatic breast cancer (MBC) database to investigate current patterns of use of oral vinorelbine (OV), as well as outcomes of patients receiving this drug.

Patients And Methods: Data were collected retrospectively from women and men treated for MBC between 2008 and 2014 at one of 18 French Comprehensive Cancer Centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14381DOI Listing

Geographical Differences in Likelihood of Home Death Among Palliative Cancer Patients: A National Population-based Register Study.

Anticancer Res 2020 Jul;40(7):3897-3903

Center for Research & Development, Uppsala University/County Council of Gävleborg, Gävle Hospital, Gävle, Sweden.

Background/aim: Previous studies have shown discrepancies between patient's desired and actual death place. As planning of family support and involvement of palliative home care teams seem to improve the chance to meet patients preferences, geographical availability of specialized palliative home care could influence place of death.

Patients And Methods: Data of patients diagnosed and deceased between January 2011 until December 2014 with lung, brain, colorectal, breast and prostate cancer was collected from Swedish national registers and multiple regression analyses were performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14380DOI Listing

Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.

Anticancer Res 2020 Jul;40(7):3889-3896

Department of Pulmonology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Background/aim: Immune checkpoint inhibitors (ICIs) have an important role in lung cancer therapy. Although the programmed cell death protein-1 (PD-L1) tumor proportion score (TPS) and tumor mutational burden are known prognostic factors, they are insufficient to predict clinical outcomes. This study was conducted to identify novel biomarkers for ICI treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14379DOI Listing

Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes.

Anticancer Res 2020 Jul;40(7):3883-3888

IGF Oncology, LLC, Saint Paul, MN, U.S.A.

Background/aim: The insulin-like growth factor type 1 receptor (IGF-1R) is overexpressed in myelodysplastic syndrome (MDS) cells, and 765IGF-Methotrexate (IGF-MTX) is a conjugate of methotrexate and a variant of insulin-like growth factor-1 (IGF-1) designed to selectively target cancer cells through binding to IGF-1R. The aim of this study was to determine whether IGF-MTX would be effective to treat MDS.

Patients And Methods: In this phase I clinical trial, two patients with high grade MDS or oligoblastic acute myeloid leukemia (O-AML) that had failed standard therapy were treated with IGF-MTX. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14378DOI Listing

Pathological Validity of Using Near-infrared Fluorescence Imaging for Securing Surgical Margins During Liver Resection.

Anticancer Res 2020 Jul;40(7):3873-3882

Department of General and Gastroenterological Surgery, Showa University School of Medicine, Tokyo, Japan.

Background/aim: This study investigated the use of near-infrared fluorescent imaging for securing safe margins during liver resection.

Patients And Methods: This study included 125 patients who underwent liver tumor resection in 2014-2018. Indocyanine green testing was performed 2-14 days before surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14377DOI Listing

Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant Ovarian Cancer Cells.

Anticancer Res 2020 Jul;40(7):3865-3872

Translational Cell Therapy Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.

Background/aim: Ovarian cancer (OC) is typically diagnosed at an advanced stage with limitations for cure. Cytokine-induced killer (CIK) T cell therapy exerts significant cytotoxic effects against cancer cells and reduces the adverse effects of chemotherapy. Herein, we performed a flow cytometry-based method to evaluate the cytotoxicity of peripheral blood mononuclear cells-derived CIK cells against OC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14376DOI Listing

Activity of Alcohol Dehydrogenase and Aldehyde Dehydrogenase in Lung Cancer Cells.

Anticancer Res 2020 Jul;40(7):3857-3863

Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland.

Background: The aim of this study was to define the alterations in the activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in normal and cancerous lung cells.

Materials And Methods: Lung tissues were taken from 36 patients during surgical resection of cancer. The activities of tested enzymes were measured by spectrofluorometric method (ADH I, ADH II, total ALDH) and photometric method (ADH III, ADH IV, total ADH). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14375DOI Listing

Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.

Anticancer Res 2020 Jul;40(7):3847-3855

Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.

Background/aim: The effects of tyrosine kinase inhibitors (TKI) in head and neck squamous cell cancer (HNSCC) are not fully understood. We investigated the effects of selective TKIs erlotinib, gefitinib, nilotinib, and dasatinib and the mTOR-inhibitor everolimus on the expression of insulin-like growth factor 1 receptor (IGF1R) in HPV-positive and HPV-negative squamous cancer cell lines.

Materials And Methods: HPV-negative UMSCC-11A and UMSCC-14C cells and HPV-positive CERV196 cells were treated with TKIs or everolimus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14374DOI Listing

Novel Prognostic Factor for Uveal Melanoma: Bioinformatics Analysis of Three Independent Cohorts.

Anticancer Res 2020 Jul;40(7):3839-3846

Department of Anatomy, School of Medicine, Pusan National University, Yangsan, Republic of Korea

Background/aim: Because 50% of uveal melanoma metastasize within 10 years of diagnosis, there is urgent need for accurate prognostic factors.

Materials And Methods: To identify genes that can act as prognostic factors in uveal melanoma, we performed survival analyses using three independent cohorts. Using log-rank test and univariate cox regression, genes which could stratify the prognosis in all cohorts simultaneously depending on their expression levels were selected as novel biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.14373DOI Listing